Top Ofloxacin Brands: Leading Choices for Reliable Treatment

When it comes to choosing the best brands for Ofloxacin, it's essential to consider their reputation for quality and efficacy. Ofloxacin, a commonly prescribed antibiotic, is available from various pharmaceutical companies that focus on ensuring consistent and reliable formulations. Brands such as Lupin, Cipla, and Zydus have established themselves as leaders in the market, providing trusted options that many healthcare professionals recommend. Other notable mentions include brands like Dr. Reddy's and Aurobindo, which also maintain high standards in their production processes. To explore a comprehensive list of top brands for Ofloxacin, continue reading below.

Illustration of ofloxacin

Best brands of ofloxacin in 2025

Cipla

Cipla Limited is a renowned producer of ofloxacin, with its Oflox 400 Tablets demonstrating bioequivalence to Tarivid(r) 400 mg tablets, ensuring effective and safe treatment for tuberculosis. The product, manufactured at Cipla's Patalganga Unit II, has met the preset acceptance limits of 80-125% for AUC and Cmax values, highlighting its clinical performance. Cipla's strong market presence is evident from its financial performance, with revenues crossing INR 25,000 Cr and operating margins improving significantly in FY24. The company's commitment to quality and efficacy is reflected in its global operations, including a 12-13% market share in Albuterol and a 20.8% market share in Lanreotide in the North American market. Cipla's continuous growth and innovation make it a leading player in the pharmaceutical industry. For more detailed information, you can refer to the WHO document that provides comprehensive product insights.

Sun Pharmaceutical Industries

Sun Pharmaceutical Industries is a leading manufacturer of ofloxacin, a synthetic fluoroquinolone antibacterial agent, known for its high-quality formulations and widespread market presence. The company's Ofloxacin Ornidazole Tablets USP are widely used to treat various bacterial and protozoal infections, including those of the respiratory tract, skin, and urinary tract. Sun Pharmaceutical Industries has a significant global footprint, contributing to the growth of the generic pharmaceuticals market, which is expected to reach $426.30 billion by 2026 at a CAGR of 6.4%. Their products are recognized for their efficacy and are manufactured in compliance with stringent quality guidelines such as WHO, FDA, and EU standards. This ensures that the medications are reliable and effective in treating infections.

Teva Pharmaceuticals

Teva Pharmaceuticals is a leading global pharmaceutical company, known for its significant contributions to the pharmaceutical industry, including its dominant position in the generic medicines segment, holding 35% of the market share in Israel and filling 25% of all prescriptions with its products. In 2023, Teva reported revenues of $15.8 billion, representing a 6% increase from 2022, driven by higher revenues from generic products and innovative drugs like AUSTEDO and AJOVY. The company's R&D expenses increased by 14% in 2023, highlighting its commitment to innovative pipelines. Despite not being specifically highlighted as a top producer of ofloxacin, Teva's broad portfolio and market influence underscore its status as a major player in the pharmaceutical industry.

Lupin Limited

Lupin Limited is a leading pharmaceutical company recognized for its high-quality production of ofloxacin, a versatile quinolone antibiotic. The company's commitment to innovation and stringent manufacturing standards has made it a trusted name in the industry. In the Indian market, Lupin Limited is one of the key players driving the growth of the ofloxacin market, expected to see steady expansion due to increasing patient awareness and the need for advanced bacterial infection treatments. Lupin's ofloxacin is available in various forms, including tablets, capsules, and eye and ear drops, catering to a wide range of applications such as chronic bronchitis, conjunctivitis, and urinary tract infections. With a strong focus on research and development, Lupin continues to enhance its market share through strategic product launches and collaborations.

Aurobindo Pharma

Aurobindo Pharma is recognized as one of the leading producers of ofloxacin, a synthetic fluoroquinolone antibacterial agent, due to its stringent quality control and compliance with international standards such as Ph.Eur. or NF requirements. The company has a robust manufacturing process, including steps like sifting, dry mixing, wet granulation, and coating, which are validated according to European guidelines. Aurobindo Pharma's ofloxacin formulations are available in various strengths, including 200mg, 400mg, and 0.3% ophthalmic solutions, and are distributed globally through a network of reputable suppliers. The company's commitment to quality is evident from its extensive validation data and bioequivalence studies, ensuring the efficacy and safety of its products. For instance, their levofloxacin formulations have demonstrated bioequivalence with reference products, with 90% confidence intervals within the acceptance range of 0.80 - 1.25. More information about their ofloxacin formulations can be found here.

Dr. Reddy's Laboratories

Dr. Reddy's Laboratories is a prominent player in the pharmaceutical industry, particularly noted for its production of ofloxacin, a quinolone antibiotic. The company, headquartered in Hyderabad, Telangana, has been a key manufacturer of ofloxacin along with other quinolone drugs like norfloxacin and ciprofloxacin. In the Indian market, Dr. Reddy's has contributed significantly to the production of these antibiotics, with the total production of norfloxacin, for example, being around 70-80 tonnes per annum. The company's efficiency in manufacturing these drugs has been a focus area, with efforts to improve the overall efficiency from about 37% to 45-50% through better process and plant engineering designs. Dr. Reddy's Laboratories has also shown strong financial performance, with revenue growth driven by its global generics segment, including significant contributions from its Indian market operations. For more details, visit Dr. Reddy's Laboratories website.

Alkem Laboratories

Alkem Laboratories Ltd. is a prominent player in the India ofloxacin market, known for its high-quality production and significant market share. The company contributes to the steady growth of the India ofloxacin market, driven by the high prevalence of bacterial infections and the increasing need for advanced drugs. As of the forecast period, the tablet segment, dominated by Alkem Laboratories, is expected to maintain its leading position due to ease of availability and high stability. The market is projected to grow steadily, with tablets being the preferred form due to their longer shelf life and ease of usage. Major companies like Alkem Laboratories are crucial in strategizing investments and capitalizing on market opportunities. For more insights on the India ofloxacin market, visit the TechSci Research report.

Glenmark Pharmaceuticals

Glenmark Pharmaceuticals is renowned for its robust performance in the pharmaceutical industry, particularly in producing high-quality formulations like ofloxacin. In the second quarter of FY 2024-25, Glenmark reported a 13.9% year-over-year growth in its India business and a 14.6% growth in its Europe operations, highlighting its strong market presence. The company's formulations business has consistently shown significant growth, with Latin America and Rest of the World (RoW) markets experiencing substantial increases in previous years. Glenmark's commitment to innovation and expanding its product portfolio, including biopharmaceuticals, further solidifies its position as a leading producer. The company's flagship products, such as RYALTRIS(r), have achieved high double-digit market shares in several European and other global markets. For more detailed information on their financial performance, you can view the official press release.

Ranbaxy Laboratories

Ranbaxy Laboratories is renowned as one of the leading producers of Ofloxacin, a potent antibacterial drug. The company was the first in India to introduce Nalidixic acid production and later pioneered the manufacture of Norfloxacin in 1988, followed by Ofloxacin. Ranbaxy's industrial license was expanded to 120 MT for four quinolone antibacterials, highlighting its significant production capacity. The company achieved a notable 68.6% increase in Ofloxacin production from 197.31 to 332.81 units, demonstrating its robust growth and competitiveness in the international market. Ranbaxy's strong in-house R&D and efficient manufacturing processes have enabled it to export bulk drugs and formulations globally. For more details, visit Ranbaxy's company history.

Sandoz

Sandoz, a division of Novartis, is a leading producer of ofloxacin, offering high-quality ophthalmic solutions like Sandoz Ofloxacin Ophthalmic Solution USP, 0.3%, which is indicated for the treatment of bacterial conjunctivitis caused by susceptible strains. This solution has been shown to achieve significant concentrations in the eye, with tear concentrations ranging from 1.2 to 22 mcg/g four hours after the first dose. The product has a strong bioavailability profile and is used only to treat proven or strongly suspected bacterial infections to prevent drug resistance. As of the 2018 revision, this product has been widely used and trusted in the medical community. Sandoz's commitment to quality and efficacy makes it a top choice for ofloxacin formulations. For more detailed information, you can view the product monograph.